A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...
Medpage Today on MSN29d
Dupilumab Improves Quality of Life for COPD PatientsAt 52 weeks, the least-squares mean difference from baseline in the total St. George's Respiratory Questionnaire (SGRQ) score ...
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
as assessed by the St. George’s Respiratory Questionnaire (SGRQ). Data from both studies were published in separate manuscripts in The New England Journal of Medicine (BOREAS and NOTUS).
A new study published in the Chest Journal showed that Dupilumab helps individuals with type 2 inflammation and chronic ...
SGRQ total score averaged over 24 wk: cilomilast improved ~3.6 points vs placebo worsened ~0.5 points (p < 0.001) pts. exacerbation-free at 24 wk: cilomilast 74% vs placebo 62% (p = 0.008 ...
In both trials, health-related quality of life was assessed using the St. George’s Respiratory Questionnaire (SGRQ) responder analysis which was defined as an improvement in SGRQ score from ...
导语：慢性阻塞性肺疾病（简称慢阻肺病）是一种常见的、可预可治的慢性气道炎症性疾病，患者通常在气候变化、季节交替时，咳、痰、喘等症状加重，且症状加重在冬季达到顶峰[1]，容易引起稳定期与急性期交替出现，导致疾病控制效果不佳，因此对稳定期患者的管理变得尤 ...
SGRQ total score averaged over 24 wk: cilomilast improved ~3.6 points vs placebo worsened ~0.5 points (p < 0.001) pts. exacerbation-free at 24 wk: cilomilast 74% vs placebo 62% (p = 0.008 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback